Loading company…
Vedere Bio II developed ocular gene therapies intended to restore vision after photoreceptor cell death.
Founded in 2019 and based in Massachusetts, US, Vedere Bio II developed gene therapies using optogenetics and AAV vectors to address vision loss caused by photoreceptor cell death. Its investors included Atlas Venture, Casdin Capital, Mission BioCapital, Octagon Capital, the RD Fund and Samsara BioCapital. The company discontinued operations in March 2023.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in